Sinsin Pharmaceutical Inkomsten in het verleden
Verleden criteriumcontroles 2/6
Sinsin Pharmaceutical has been growing earnings at an average annual rate of 29.3%, while the Pharmaceuticals industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 11.3% per year. Sinsin Pharmaceutical's return on equity is 6.2%, and it has net margins of 3.8%.
Belangrijke informatie
29.3%
Groei van de winst
29.3%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 11.3% |
| Inkomstengroei | 11.3% |
| Rendement op eigen vermogen | 6.2% |
| Nettomarge | 3.8% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
What Sinsin Pharmaceutical Co., Ltd's (KOSDAQ:002800) 40% Share Price Gain Is Not Telling You
Jul 30
Sinsin Pharmaceutical's (KOSDAQ:002800) Profits May Not Reveal Underlying Issues
Mar 20What Kind Of Shareholders Hold The Majority In Sinsin Pharmaceutical Co., Ltd's (KOSDAQ:002800) Shares?
Mar 06Is Sinsin Pharmaceutical (KOSDAQ:002800) A Risky Investment?
Feb 08
If You Had Bought Sinsin Pharmaceutical (KOSDAQ:002800) Stock A Year Ago, You Could Pocket A 24% Gain Today
Jan 18We're Not Counting On Sinsin Pharmaceutical (KOSDAQ:002800) To Sustain Its Statutory Profitability
Dec 25What Kind Of Investors Own Most Of Sinsin Pharmaceutical Co., Ltd (KOSDAQ:002800)?
Nov 29Opbrengsten en kosten
Hoe Sinsin Pharmaceutical geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 105,246 | 4,049 | 26,976 | 559 |
| 31 Mar 24 | 103,826 | 4,314 | 26,644 | 503 |
| 31 Dec 23 | 102,586 | 4,680 | 25,695 | 488 |
| 30 Sep 23 | 100,691 | 4,899 | 25,271 | 415 |
| 30 Jun 23 | 98,396 | 5,249 | 24,806 | 435 |
| 31 Mar 23 | 96,259 | 4,683 | 23,965 | 127 |
| 31 Dec 22 | 91,926 | 4,415 | 23,610 | 90 |
| 30 Sep 22 | 87,295 | 4,267 | 22,580 | 167 |
| 30 Jun 22 | 82,522 | 2,554 | 22,185 | 210 |
| 31 Mar 22 | 76,934 | -202 | 22,235 | 473 |
| 31 Dec 21 | 74,008 | -1,476 | 21,279 | 709 |
| 30 Sep 21 | 72,585 | -2,848 | 21,097 | 1,149 |
| 30 Jun 21 | 71,022 | -489 | 21,117 | 1,045 |
| 31 Mar 21 | 68,078 | -1,239 | 20,983 | 1,029 |
| 31 Dec 20 | 67,129 | 363 | 20,881 | 785 |
| 30 Sep 20 | 66,188 | 1,695 | 20,586 | 299 |
| 30 Jun 20 | 65,909 | 266 | 20,552 | 257 |
| 31 Mar 20 | 67,120 | 2,086 | 20,274 | 563 |
| 31 Dec 19 | 67,855 | 2,138 | 19,954 | 576 |
| 30 Sep 19 | 67,066 | 2,857 | 19,407 | 494 |
| 30 Jun 19 | 65,868 | 2,572 | 19,103 | 480 |
| 31 Mar 19 | 64,679 | 2,998 | 18,568 | 175 |
| 31 Dec 18 | 63,720 | 2,896 | 18,444 | 160 |
| 30 Sep 18 | 62,879 | 2,910 | 18,102 | 158 |
| 30 Jun 18 | 61,700 | 3,222 | 17,381 | 161 |
| 31 Mar 18 | 61,001 | 3,425 | 16,672 | 144 |
| 31 Dec 17 | 61,733 | 3,605 | 16,589 | 139 |
| 30 Sep 17 | 61,370 | 4,079 | 16,312 | 112 |
| 30 Jun 17 | 60,370 | 4,016 | 15,914 | 93 |
| 31 Mar 17 | 59,926 | 4,472 | 15,516 | 92 |
| 31 Dec 16 | 58,069 | 4,441 | 15,057 | 75 |
Kwaliteitswinsten: A002800 has high quality earnings.
Groeiende winstmarge: A002800's current net profit margins (3.8%) are lower than last year (5.3%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: A002800's earnings have grown significantly by 29.3% per year over the past 5 years.
Versnelling van de groei: A002800's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: A002800 had negative earnings growth (-22.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (21.9%).
Rendement op eigen vermogen
Hoge ROE: A002800's Return on Equity (6.2%) is considered low.